Natera, Inc. (NASDAQ:NTRA) Shares Purchased by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC raised its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 372.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 331 shares of the medical research company’s stock after buying an additional 261 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Natera were worth $52,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Wellington Management Group LLP grew its holdings in Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after buying an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Natera by 3.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after buying an additional 85,236 shares during the last quarter. Geode Capital Management LLC grew its holdings in Natera by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after buying an additional 143,825 shares during the last quarter. Maverick Capital Ltd. grew its holdings in Natera by 25.2% during the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock valued at $170,119,000 after buying an additional 269,706 shares during the last quarter. Finally, Castle Hook Partners LP lifted its stake in shares of Natera by 27.4% during the 3rd quarter. Castle Hook Partners LP now owns 1,140,090 shares of the medical research company’s stock worth $144,734,000 after purchasing an additional 245,505 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on NTRA shares. Piper Sandler increased their price target on Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. Guggenheim increased their price target on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Robert W. Baird increased their price target on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. JPMorgan Chase & Co. increased their price target on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $178.12.

Insider Activity

In other news, insider John Fesko sold 669 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $159.60, for a total transaction of $106,772.40. Following the completion of the sale, the insider now directly owns 114,142 shares in the company, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Burkes Brophy sold 792 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $146.04, for a total value of $115,663.68. Following the sale, the chief financial officer now owns 71,869 shares of the company’s stock, valued at $10,495,748.76. This represents a 1.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 307,466 shares of company stock worth $49,047,655 over the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Natera Trading Up 3.1 %

NASDAQ:NTRA opened at $150.87 on Thursday. The business’s 50-day moving average is $162.25 and its two-hundred day moving average is $149.27. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00. The firm has a market capitalization of $20.40 billion, a PE ratio of -85.72 and a beta of 1.80.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.